midpage
Projects
Sign in to see your projects.
799 F.3d 202
2d Cir.
2015
Read the full case

Background

  • Twenty-eight independent retail pharmacies (plaintiffs) sued pharmaceutical manufacturers and certain large purchasers, alleging Robinson-Patman Act price discrimination (discounts/rebates to "favored purchasers" such as HMOs and PBMs) harmed their competitive position and caused lost customers and damages.
  • Plaintiffs had earlier opted out of a larger MDL Sherman Act case, settled Sherman Act claims, and proceeded on Robinson-Patman claims in the Eastern District of New York; extended discovery followed, including a court-supervised matching process to identify customers plaintiffs allegedly lost to five favored purchasers (1998–2010).
  • The matching process produced very few confirmed lost customers: ~3% of potential lost customers matched to favored purchasers; average per-pharmacy loss ≈ 18 customers and 54 transactions per year—de minimis relative to typical annual prescription volume.
  • Defendants moved for summary judgment; the district court concluded plaintiffs failed to show competitive injury (required for Robinson-Patman §2(a)) and antitrust injury (required for damages), and denied injunctive relief as unlikely given lack of past injury; judgment for defendants was entered and appealed.
  • The Second Circuit affirmed, holding the de minimis diverted sales rebutted any Morton Salt inference and were insufficient to show competitive injury, antitrust injury, or a likelihood of future injury for injunctive relief; §2(d) and §2(f) claims likewise failed for lack of antitrust injury.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether plaintiffs proved competitive (secondary-line) injury under Robinson-Patman §2(a) Price discrimination to favored purchasers diverted customers and substantially harmed plaintiffs' competition Matching data show only de minimis diversion; no substantial effect on competition Plaintiffs failed to show competitive injury; summary judgment affirmed
Whether Morton Salt inference (inference of injury from substantial price differences over time) applies or is rebutted Substantial discounts over time plus some evidence of diverted sales warrant the Morton Salt inference and a trial The inference is rebuttable; defendants’ evidence of de minimis diversion rebuts it Morton Salt inference was rebutted by the matching results; cannot be treated as irrebuttable
Whether plaintiffs proved antitrust injury (required for damages) Loss of customers and sales from price discrimination caused plaintiffs’ damages De minimis losses do not show the type and causation of injury the antitrust laws protect Plaintiffs failed to show antitrust injury; damages claim fails
Whether injunctive relief under Clayton Act §16 is appropriate Ongoing discriminatory pricing justifies injunction to prevent future injury Long-running practice produced no past injury; lack of past injury makes future injury unlikely Injunctive relief denied because plaintiffs cannot show a reasonable probability of future antitrust injury
Whether claims under Robinson-Patman §§2(d) and 2(f) survive given §2(a) failure §2(d) and §2(f) liability independent or distinct; plaintiffs can prevail even if §2(a) fails §2(d) still requires antitrust injury for damages; §2(f) depends on seller liability under other sections §§2(d) and 2(f) claims fail for lack of antitrust/competitive injury

Key Cases Cited

  • Volvo Trucks N. Am. v. Reeder-Simco GMC, 546 U.S. 164 (2006) (hallmark of secondary-line injury is diversion of sales to favored purchaser; small diversions can be insubstantial)
  • FTC v. Morton Salt Co., 334 U.S. 37 (1948) (permissible inference of competitive injury from substantial price differences over time)
  • Falls City Indus., Inc. v. Vaneo Beverage, Inc., 460 U.S. 428 (1983) (Morton Salt inference restated; inference can be rebutted)
  • Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc., 429 U.S. 477 (1977) (distinguishing competitive injury from antitrust injury for damages)
  • J. Truett Payne Co. v. Chrysler Motors Corp., 451 U.S. 557 (1981) (plaintiff must show antitrust injury to recover damages)
  • George Haug Co. v. Rolls Royce Motor Cars Inc., 148 F.3d 136 (2d Cir. 1998) (elements for establishing secondary-line Robinson-Patman claim)
  • Boise Cascade Corp. v. FTC, 837 F.2d 1127 (D.C. Cir. 1988) (evidence showing no competitive injury defeats Morton Salt inference)
  • H.L. Hayden Co. of New York v. Siemens Med. Sys., 879 F.2d 1005 (2d Cir. 1989) (insufficient proof connecting losses to alleged Robinson-Patman violations defeats antitrust damages)
Read the full case

Case Details

Case Name: Cash & Henderson Drugs, Inc. v. Johnson & Johnson, Caremark L.L.C.
Court Name: Court of Appeals for the Second Circuit
Date Published: Aug 27, 2015
Citations: 799 F.3d 202; 2015 WL 5047409; 2015 U.S. App. LEXIS 15162; 12-4689
Docket Number: 12-4689
Court Abbreviation: 2d Cir.
Log In
    Cash & Henderson Drugs, Inc. v. Johnson & Johnson, Caremark L.L.C., 799 F.3d 202